View clinical trials related to Arrhythmia.
Filter by:To examine the relationships among psychosocial factors and carotid atherosclerosis, myocardial ischemia, arrhythmias, and thrombosis.
To determine whether treatment with antidepressant, anticonvulsant, and antiarrhythmic drug therapies having the potential for proarrhythmia increased the risk of primary cardiac arrest. The aim of the original grant, starting in 1990 and ending in 1994, was to determine whether use of diuretics for hypertension increased the risk of primary cardiac arrest compared to the use of other antihypertensive agents.
To investigate factors which trigger the discharge of implantable cardioverter-defibrillators (ICDs).
To acquire a better understanding of the spontaneous clinical behavior of paroxysmal tachycardia by studying epidemiologic features of symptomatic tachycardia patients.
To determine if silent myocardial ischemia was associated with an increased risk of cardiac mortality and morbidity during a one to three year follow-up in patients with coronary heart disease.
To validate two models which categorized patients with syncope into high and low risk for either sudden death or diagnostic arrhythmias based on data available from the initial history, physical examination, and electrocardiogram.
To assess factors associated with safety and efficacy of catheter ablation using direct current or radiofrequency energy for the management of patients with drug and/or pacemaker resistant cardiac arrhythmias.
To measure survival to hospital discharge of patients with out-of-hospital cardiac arrest in community units (e.g., apartment or office buildings, gated communities, sports venues, senior centers, shopping malls) served by trained non-medical responders using automated external defibrillators (AEDs), an approach called Public Access Defibrillation, compared to units receiving the traditional optimum community standard of care (i.e., rescuers trained to recognize a cardiac emergency, call 911, and initiate CPR).
To determine if the dietary N-3 class of polyunsaturated fatty acids (PUFAs) provided in the diet largely from marine fish oils would prevent fatal ventricular tachycardia (VT) or ventricular fibrillation (VF).
To determine the antiarrhythmic effects of dietary N-3 fatty acids in patients with implanted defibrillators.